Table 2.
ITT population characteristics at entry
| Placebo |
Riluzole |
|||
|---|---|---|---|---|
| PSP, n = 181 | MSA, n = 199 | PSP, n = 181 | MSA, n = 199 | |
| Sex | ||||
| Female (%) | 40.3 | 44.2 | 44.8 | 46.2 |
| Age at entry (years)* | 67.7 ± 7.0 | 62.6 ± 8.1 | 68.0 ± 6.6 | 61.9 ± 8.5 |
| Age at onset (years)* | 63.8 ± 7.0 | 58.2 ± 8.3 | 63.9 ± 7.0 | 57.3 ± 8.6 |
| Disease duration (years)* | 3.9 ± 1.9 | 4.4 ± 2 | 4.1 ± 1.9 | 4.5 ± 1.9 |
| Short Motor Disability Scale (0–17) | 6.4 ± 3.7 | 6.1 ± 3.9 | 6.7 ± 3.6 | 6.1 ± 3.6 |
| Frontal Assessment Battery (0–18)* | 11.1 ± 4.3 | 14.6 ± 3.2 | 11.3 ± 4.1 | 14.3 ± 3.3 |
| Mini-Mental Status Examination (0–30)* | 25.4 ± 4.4 | 27.8 ± 2.3 | 25.2 ± 4.4 | 27.6 ± 2.5 |
| Schwab & England Activity Daily Living (0–100)* | 50.2 ± 24.5a | 53.8 ± 24.8 | 48.3 ± 23.6 | 53.3 ± 24.3 |
| Hoehn and Yahr Staging (0–5)* | 3.6 ± 1.0 | 3.4 ± 1.0 | 3.6 ± 0.9 | 3.5 ± 1.0 |
| Clinician Global Impression Disease severity (0–6)* | 3.6 ± 1.0 | 3.6 ± 1.0 | 3.7 ± 1.0 | 3.6 ± 0.9 |
| Clinician Global Impression Dysautonomia (0–3)* | 0.6 ± 0.6 | 1.8 ± 0.8 | 0.6 ± 0.6 | 1.8 ± 0.8 |
Quantitative variables were analysed using variance analysis and categorical data using a log-linear model. Factors included in models were strata, treatment, country and strata by treatment interactions. Significance was set at P < 0.05 (two-tailed test) for each factor or interaction. No differences related to treatment group were detected at entry for the whole population or within strata. All values are mean ± SD.
a n = 180 due to one missing value.
*Differences between PSP and MSA strata (P < 0.05; two-tailed test) were found for all variables except for sex and the Short Motor Disability Scale score.